nodes	percent_of_prediction	percent_of_DWPC	metapath
Pioglitazone—CYP3A4—bone cancer	0.62	1	CbGaD
Pioglitazone—SLCO1B3—Methotrexate—bone cancer	0.112	0.473	CbGbCtD
Pioglitazone—SLCO1B1—Methotrexate—bone cancer	0.0654	0.276	CbGbCtD
Pioglitazone—CYP2C9—Cisplatin—bone cancer	0.0298	0.125	CbGbCtD
Pioglitazone—CYP2D6—Doxorubicin—bone cancer	0.0182	0.0768	CbGbCtD
Pioglitazone—CYP3A4—Doxorubicin—bone cancer	0.0116	0.0488	CbGbCtD
Pioglitazone—SLCO1B1—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.00191	0.0471	CbGpPWpGaD
Pioglitazone—SLCO1B1—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.00179	0.0441	CbGpPWpGaD
Pioglitazone—PPARG—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.0013	0.0322	CbGpPWpGaD
Pioglitazone—SLCO1B1—Irinotecan Pathway—CYP3A4—bone cancer	0.00122	0.0301	CbGpPWpGaD
Pioglitazone—PPARG—Nuclear Receptors—NR1I2—bone cancer	0.00119	0.0294	CbGpPWpGaD
Pioglitazone—Fracture—Methotrexate—bone cancer	0.00111	0.0111	CcSEcCtD
Pioglitazone—Multiple fractures—Methotrexate—bone cancer	0.00111	0.0111	CcSEcCtD
Pioglitazone—CYP2C8—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00109	0.0269	CbGpPWpGaD
Pioglitazone—Polyp—Methotrexate—bone cancer	0.00106	0.0106	CcSEcCtD
Pioglitazone—SLCO1B1—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.00105	0.0258	CbGpPWpGaD
Pioglitazone—CYP2C8—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.00104	0.0257	CbGpPWpGaD
Pioglitazone—Generalised oedema—Epirubicin—bone cancer	0.00101	0.0102	CcSEcCtD
Pioglitazone—Polyp—Epirubicin—bone cancer	0.000992	0.00995	CcSEcCtD
Pioglitazone—CYP2C19—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000975	0.024	CbGpPWpGaD
Pioglitazone—Cyst—Methotrexate—bone cancer	0.000965	0.00967	CcSEcCtD
Pioglitazone—Liver disorder—Methotrexate—bone cancer	0.000946	0.00949	CcSEcCtD
Pioglitazone—PPARG—Nuclear Receptor transcription pathway—NR1I2—bone cancer	0.000943	0.0233	CbGpPWpGaD
Pioglitazone—Cardiac failure congestive—Cisplatin—bone cancer	0.000941	0.00943	CcSEcCtD
Pioglitazone—Generalised oedema—Doxorubicin—bone cancer	0.000939	0.00941	CcSEcCtD
Pioglitazone—Polyp—Doxorubicin—bone cancer	0.000918	0.0092	CcSEcCtD
Pioglitazone—Cyst—Epirubicin—bone cancer	0.000903	0.00905	CcSEcCtD
Pioglitazone—CYP2D6—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.000901	0.0222	CbGpPWpGaD
Pioglitazone—CYP2D6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000897	0.0221	CbGpPWpGaD
Pioglitazone—CYP2C9—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000889	0.0219	CbGpPWpGaD
Pioglitazone—Cerebrovascular accident—Cisplatin—bone cancer	0.000871	0.00873	CcSEcCtD
Pioglitazone—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.00085	0.021	CbGpPWpGaD
Pioglitazone—Cyst—Doxorubicin—bone cancer	0.000836	0.00838	CcSEcCtD
Pioglitazone—Breast disorder—Cisplatin—bone cancer	0.000771	0.00773	CcSEcCtD
Pioglitazone—PPARG—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000762	0.0188	CbGpPWpGaD
Pioglitazone—Glycosuria—Epirubicin—bone cancer	0.000745	0.00747	CcSEcCtD
Pioglitazone—Proteinuria—Methotrexate—bone cancer	0.000734	0.00736	CcSEcCtD
Pioglitazone—Protein urine present—Methotrexate—bone cancer	0.000724	0.00726	CcSEcCtD
Pioglitazone—Glycosuria—Doxorubicin—bone cancer	0.000689	0.00691	CcSEcCtD
Pioglitazone—Hepatic enzyme increased—Methotrexate—bone cancer	0.000682	0.00684	CcSEcCtD
Pioglitazone—Acute coronary syndrome—Cisplatin—bone cancer	0.000648	0.0065	CcSEcCtD
Pioglitazone—Myocardial infarction—Cisplatin—bone cancer	0.000645	0.00646	CcSEcCtD
Pioglitazone—PPARG—Circadian rythm related genes—TNFRSF11A—bone cancer	0.000599	0.0148	CbGpPWpGaD
Pioglitazone—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000586	0.0145	CbGpPWpGaD
Pioglitazone—Neoplasm—Methotrexate—bone cancer	0.000583	0.00585	CcSEcCtD
Pioglitazone—Urinary tract disorder—Cisplatin—bone cancer	0.000583	0.00584	CcSEcCtD
Pioglitazone—Connective tissue disorder—Cisplatin—bone cancer	0.00058	0.00582	CcSEcCtD
Pioglitazone—Urethral disorder—Cisplatin—bone cancer	0.000579	0.0058	CcSEcCtD
Pioglitazone—Pulmonary oedema—Methotrexate—bone cancer	0.000574	0.00576	CcSEcCtD
Pioglitazone—Fluid retention—Epirubicin—bone cancer	0.000573	0.00575	CcSEcCtD
Pioglitazone—Visual impairment—Cisplatin—bone cancer	0.000569	0.0057	CcSEcCtD
Pioglitazone—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL3—bone cancer	0.00056	0.0138	CbGpPWpGaD
Pioglitazone—Cramps of lower extremities—Epirubicin—bone cancer	0.000555	0.00556	CcSEcCtD
Pioglitazone—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000552	0.0136	CbGpPWpGaD
Pioglitazone—Eye disorder—Cisplatin—bone cancer	0.000552	0.00553	CcSEcCtD
Pioglitazone—Cardiac disorder—Cisplatin—bone cancer	0.000548	0.00549	CcSEcCtD
Pioglitazone—Neoplasm—Epirubicin—bone cancer	0.000546	0.00547	CcSEcCtD
Pioglitazone—Diabetes mellitus—Methotrexate—bone cancer	0.000538	0.0054	CcSEcCtD
Pioglitazone—Pulmonary oedema—Epirubicin—bone cancer	0.000537	0.00539	CcSEcCtD
Pioglitazone—Immune system disorder—Cisplatin—bone cancer	0.000533	0.00535	CcSEcCtD
Pioglitazone—Mediastinal disorder—Cisplatin—bone cancer	0.000532	0.00533	CcSEcCtD
Pioglitazone—Fluid retention—Doxorubicin—bone cancer	0.00053	0.00532	CcSEcCtD
Pioglitazone—CYP2C8—Xenobiotics—CYP3A4—bone cancer	0.000527	0.013	CbGpPWpGaD
Pioglitazone—Abnormal vision—Epirubicin—bone cancer	0.000526	0.00528	CcSEcCtD
Pioglitazone—Hepatic failure—Methotrexate—bone cancer	0.000521	0.00522	CcSEcCtD
Pioglitazone—CYP2D6—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000517	0.0128	CbGpPWpGaD
Pioglitazone—Malnutrition—Cisplatin—bone cancer	0.000514	0.00515	CcSEcCtD
Pioglitazone—Cramps of lower extremities—Doxorubicin—bone cancer	0.000513	0.00514	CcSEcCtD
Pioglitazone—CYP2C8—Tamoxifen metabolism—CYP3A4—bone cancer	0.000507	0.0125	CbGpPWpGaD
Pioglitazone—Flatulence—Cisplatin—bone cancer	0.000506	0.00508	CcSEcCtD
Pioglitazone—Neoplasm—Doxorubicin—bone cancer	0.000505	0.00506	CcSEcCtD
Pioglitazone—Diabetes mellitus—Epirubicin—bone cancer	0.000504	0.00505	CcSEcCtD
Pioglitazone—Pulmonary oedema—Doxorubicin—bone cancer	0.000497	0.00498	CcSEcCtD
Pioglitazone—Visual disturbance—Methotrexate—bone cancer	0.000494	0.00495	CcSEcCtD
Pioglitazone—Muscle spasms—Cisplatin—bone cancer	0.000494	0.00495	CcSEcCtD
Pioglitazone—Hepatic failure—Epirubicin—bone cancer	0.000488	0.00489	CcSEcCtD
Pioglitazone—Abnormal vision—Doxorubicin—bone cancer	0.000487	0.00488	CcSEcCtD
Pioglitazone—Cardiac failure congestive—Epirubicin—bone cancer	0.000483	0.00484	CcSEcCtD
Pioglitazone—PPARG—Generic Transcription Pathway—ZNF77—bone cancer	0.000481	0.0119	CbGpPWpGaD
Pioglitazone—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—bone cancer	0.000481	0.0119	CbGpPWpGaD
Pioglitazone—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00048	0.0118	CbGpPWpGaD
Pioglitazone—Cerebrovascular accident—Methotrexate—bone cancer	0.000478	0.00479	CcSEcCtD
Pioglitazone—Ill-defined disorder—Cisplatin—bone cancer	0.000477	0.00478	CcSEcCtD
Pioglitazone—Anaemia—Cisplatin—bone cancer	0.000475	0.00476	CcSEcCtD
Pioglitazone—CYP2C19—Xenobiotics—CYP3A4—bone cancer	0.000471	0.0116	CbGpPWpGaD
Pioglitazone—CYP2C8—Metapathway biotransformation—CYP4V2—bone cancer	0.00047	0.0116	CbGpPWpGaD
Pioglitazone—Increased appetite—Epirubicin—bone cancer	0.000466	0.00468	CcSEcCtD
Pioglitazone—Diabetes mellitus—Doxorubicin—bone cancer	0.000466	0.00467	CcSEcCtD
Pioglitazone—Malaise—Cisplatin—bone cancer	0.000463	0.00465	CcSEcCtD
Pioglitazone—CYP2C19—Tamoxifen metabolism—CYP3A4—bone cancer	0.000453	0.0112	CbGpPWpGaD
Pioglitazone—Hepatic failure—Doxorubicin—bone cancer	0.000451	0.00452	CcSEcCtD
Pioglitazone—Hypoglycaemia—Epirubicin—bone cancer	0.000449	0.0045	CcSEcCtD
Pioglitazone—Cardiac failure—Epirubicin—bone cancer	0.000449	0.0045	CcSEcCtD
Pioglitazone—Cerebrovascular accident—Epirubicin—bone cancer	0.000447	0.00448	CcSEcCtD
Pioglitazone—Cardiac failure congestive—Doxorubicin—bone cancer	0.000447	0.00448	CcSEcCtD
Pioglitazone—Pain in extremity—Epirubicin—bone cancer	0.000438	0.00439	CcSEcCtD
Pioglitazone—Myalgia—Cisplatin—bone cancer	0.000437	0.00439	CcSEcCtD
Pioglitazone—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000434	0.00436	CcSEcCtD
Pioglitazone—CYP2D6—Xenobiotics—CYP3A4—bone cancer	0.000433	0.0107	CbGpPWpGaD
Pioglitazone—Liver function test abnormal—Methotrexate—bone cancer	0.000432	0.00433	CcSEcCtD
Pioglitazone—Discomfort—Cisplatin—bone cancer	0.000432	0.00433	CcSEcCtD
Pioglitazone—Increased appetite—Doxorubicin—bone cancer	0.000432	0.00433	CcSEcCtD
Pioglitazone—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.000429	0.0106	CbGpPWpGaD
Pioglitazone—Breast disorder—Methotrexate—bone cancer	0.000423	0.00424	CcSEcCtD
Pioglitazone—CYP2C19—Metapathway biotransformation—CYP4V2—bone cancer	0.00042	0.0103	CbGpPWpGaD
Pioglitazone—Oedema—Cisplatin—bone cancer	0.000419	0.0042	CcSEcCtD
Pioglitazone—Anaphylactic shock—Cisplatin—bone cancer	0.000419	0.0042	CcSEcCtD
Pioglitazone—PPARG—periosteum—bone cancer	0.000418	0.22	CbGeAlD
Pioglitazone—Infection—Cisplatin—bone cancer	0.000417	0.00418	CcSEcCtD
Pioglitazone—CYP2D6—Tamoxifen metabolism—CYP3A4—bone cancer	0.000416	0.0103	CbGpPWpGaD
Pioglitazone—Cardiac failure—Doxorubicin—bone cancer	0.000415	0.00417	CcSEcCtD
Pioglitazone—Hypoglycaemia—Doxorubicin—bone cancer	0.000415	0.00417	CcSEcCtD
Pioglitazone—Cerebrovascular accident—Doxorubicin—bone cancer	0.000414	0.00415	CcSEcCtD
Pioglitazone—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.000413	0.0102	CbGpPWpGaD
Pioglitazone—Nervous system disorder—Cisplatin—bone cancer	0.000411	0.00412	CcSEcCtD
Pioglitazone—Skin disorder—Cisplatin—bone cancer	0.000407	0.00408	CcSEcCtD
Pioglitazone—Pain in extremity—Doxorubicin—bone cancer	0.000405	0.00406	CcSEcCtD
Pioglitazone—Hyperhidrosis—Cisplatin—bone cancer	0.000405	0.00406	CcSEcCtD
Pioglitazone—Liver function test abnormal—Epirubicin—bone cancer	0.000405	0.00406	CcSEcCtD
Pioglitazone—Abdominal pain upper—Epirubicin—bone cancer	0.0004	0.00401	CcSEcCtD
Pioglitazone—Breast disorder—Epirubicin—bone cancer	0.000396	0.00397	CcSEcCtD
Pioglitazone—Alanine aminotransferase increased—Epirubicin—bone cancer	0.000386	0.00387	CcSEcCtD
Pioglitazone—CYP2D6—Metapathway biotransformation—CYP4V2—bone cancer	0.000386	0.00952	CbGpPWpGaD
Pioglitazone—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.000383	0.00943	CbGpPWpGaD
Pioglitazone—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000382	0.00383	CcSEcCtD
Pioglitazone—Influenza—Epirubicin—bone cancer	0.000379	0.0038	CcSEcCtD
Pioglitazone—PTGS1—Overview of nanoparticle effects—PTGS2—bone cancer	0.000377	0.00929	CbGpPWpGaD
Pioglitazone—Upper respiratory tract infection—Methotrexate—bone cancer	0.000376	0.00377	CcSEcCtD
Pioglitazone—Liver function test abnormal—Doxorubicin—bone cancer	0.000374	0.00375	CcSEcCtD
Pioglitazone—Dyspnoea—Cisplatin—bone cancer	0.000374	0.00375	CcSEcCtD
Pioglitazone—Erectile dysfunction—Methotrexate—bone cancer	0.000373	0.00374	CcSEcCtD
Pioglitazone—Abdominal pain upper—Doxorubicin—bone cancer	0.00037	0.00371	CcSEcCtD
Pioglitazone—Angina pectoris—Epirubicin—bone cancer	0.000369	0.0037	CcSEcCtD
Pioglitazone—Breast disorder—Doxorubicin—bone cancer	0.000366	0.00367	CcSEcCtD
Pioglitazone—Bronchitis—Epirubicin—bone cancer	0.000364	0.00365	CcSEcCtD
Pioglitazone—Gastrointestinal disorder—Cisplatin—bone cancer	0.000362	0.00363	CcSEcCtD
Pioglitazone—Infestation—Methotrexate—bone cancer	0.000361	0.00362	CcSEcCtD
Pioglitazone—Infestation NOS—Methotrexate—bone cancer	0.000361	0.00362	CcSEcCtD
Pioglitazone—Alanine aminotransferase increased—Doxorubicin—bone cancer	0.000358	0.00359	CcSEcCtD
Pioglitazone—Upper respiratory tract infection—Epirubicin—bone cancer	0.000352	0.00353	CcSEcCtD
Pioglitazone—Influenza—Doxorubicin—bone cancer	0.00035	0.00351	CcSEcCtD
Pioglitazone—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CDK4—bone cancer	0.000347	0.00856	CbGpPWpGaD
Pioglitazone—Sweating—Methotrexate—bone cancer	0.000346	0.00347	CcSEcCtD
Pioglitazone—Feeling abnormal—Cisplatin—bone cancer	0.000346	0.00346	CcSEcCtD
Pioglitazone—Weight increased—Epirubicin—bone cancer	0.000345	0.00346	CcSEcCtD
Pioglitazone—Haematuria—Methotrexate—bone cancer	0.000344	0.00345	CcSEcCtD
Pioglitazone—Weight decreased—Epirubicin—bone cancer	0.000343	0.00344	CcSEcCtD
Pioglitazone—Hyperglycaemia—Epirubicin—bone cancer	0.000342	0.00343	CcSEcCtD
Pioglitazone—Angina pectoris—Doxorubicin—bone cancer	0.000341	0.00342	CcSEcCtD
Pioglitazone—Infestation NOS—Epirubicin—bone cancer	0.000338	0.00339	CcSEcCtD
Pioglitazone—Infestation—Epirubicin—bone cancer	0.000338	0.00339	CcSEcCtD
Pioglitazone—Bronchitis—Doxorubicin—bone cancer	0.000337	0.00338	CcSEcCtD
Pioglitazone—PPARG—leg—bone cancer	0.000333	0.176	CbGeAlD
Pioglitazone—PPARG—forelimb—bone cancer	0.000331	0.174	CbGeAlD
Pioglitazone—Urinary tract infection—Epirubicin—bone cancer	0.000328	0.00329	CcSEcCtD
Pioglitazone—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000326	0.00327	CcSEcCtD
Pioglitazone—Hepatitis—Methotrexate—bone cancer	0.000324	0.00325	CcSEcCtD
Pioglitazone—Sweating—Epirubicin—bone cancer	0.000324	0.00325	CcSEcCtD
Pioglitazone—CYP2C19—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000323	0.00797	CbGpPWpGaD
Pioglitazone—Haematuria—Epirubicin—bone cancer	0.000322	0.00323	CcSEcCtD
Pioglitazone—Pharyngitis—Methotrexate—bone cancer	0.000322	0.00322	CcSEcCtD
Pioglitazone—Urinary tract disorder—Methotrexate—bone cancer	0.00032	0.00321	CcSEcCtD
Pioglitazone—Weight increased—Doxorubicin—bone cancer	0.000319	0.0032	CcSEcCtD
Pioglitazone—Urethral disorder—Methotrexate—bone cancer	0.000318	0.00318	CcSEcCtD
Pioglitazone—Weight decreased—Doxorubicin—bone cancer	0.000317	0.00318	CcSEcCtD
Pioglitazone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000317	0.00781	CbGpPWpGaD
Pioglitazone—Sinusitis—Epirubicin—bone cancer	0.000317	0.00318	CcSEcCtD
Pioglitazone—Hyperglycaemia—Doxorubicin—bone cancer	0.000316	0.00317	CcSEcCtD
Pioglitazone—PTGS1—Eicosanoid Synthesis—PTGS2—bone cancer	0.000313	0.00771	CbGpPWpGaD
Pioglitazone—Infestation—Doxorubicin—bone cancer	0.000312	0.00313	CcSEcCtD
Pioglitazone—Infestation NOS—Doxorubicin—bone cancer	0.000312	0.00313	CcSEcCtD
Pioglitazone—Visual impairment—Methotrexate—bone cancer	0.000312	0.00313	CcSEcCtD
Pioglitazone—Hypersensitivity—Cisplatin—bone cancer	0.000309	0.0031	CcSEcCtD
Pioglitazone—Urinary tract infection—Doxorubicin—bone cancer	0.000304	0.00304	CcSEcCtD
Pioglitazone—Hepatitis—Epirubicin—bone cancer	0.000303	0.00304	CcSEcCtD
Pioglitazone—Eye disorder—Methotrexate—bone cancer	0.000303	0.00303	CcSEcCtD
Pioglitazone—Hypoaesthesia—Epirubicin—bone cancer	0.000302	0.00302	CcSEcCtD
Pioglitazone—Asthenia—Cisplatin—bone cancer	0.000301	0.00302	CcSEcCtD
Pioglitazone—Pharyngitis—Epirubicin—bone cancer	0.000301	0.00302	CcSEcCtD
Pioglitazone—Cardiac disorder—Methotrexate—bone cancer	0.000301	0.00301	CcSEcCtD
Pioglitazone—Sweating—Doxorubicin—bone cancer	0.0003	0.003	CcSEcCtD
Pioglitazone—Urinary tract disorder—Epirubicin—bone cancer	0.000299	0.003	CcSEcCtD
Pioglitazone—Oedema peripheral—Epirubicin—bone cancer	0.000299	0.00299	CcSEcCtD
Pioglitazone—Haematuria—Doxorubicin—bone cancer	0.000298	0.00299	CcSEcCtD
Pioglitazone—Connective tissue disorder—Epirubicin—bone cancer	0.000298	0.00299	CcSEcCtD
Pioglitazone—PPARG—hindlimb—bone cancer	0.000298	0.157	CbGeAlD
Pioglitazone—Urethral disorder—Epirubicin—bone cancer	0.000297	0.00298	CcSEcCtD
Pioglitazone—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000295	0.00726	CbGpPWpGaD
Pioglitazone—Sinusitis—Doxorubicin—bone cancer	0.000293	0.00294	CcSEcCtD
Pioglitazone—Immune system disorder—Methotrexate—bone cancer	0.000293	0.00293	CcSEcCtD
Pioglitazone—Visual impairment—Epirubicin—bone cancer	0.000292	0.00293	CcSEcCtD
Pioglitazone—Mediastinal disorder—Methotrexate—bone cancer	0.000292	0.00293	CcSEcCtD
Pioglitazone—Diarrhoea—Cisplatin—bone cancer	0.000287	0.00288	CcSEcCtD
Pioglitazone—Eye disorder—Epirubicin—bone cancer	0.000283	0.00284	CcSEcCtD
Pioglitazone—Malnutrition—Methotrexate—bone cancer	0.000282	0.00283	CcSEcCtD
Pioglitazone—Cardiac disorder—Epirubicin—bone cancer	0.000281	0.00282	CcSEcCtD
Pioglitazone—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000281	0.00692	CbGpPWpGaD
Pioglitazone—Hepatitis—Doxorubicin—bone cancer	0.00028	0.00281	CcSEcCtD
Pioglitazone—Hypoaesthesia—Doxorubicin—bone cancer	0.000279	0.0028	CcSEcCtD
Pioglitazone—Pharyngitis—Doxorubicin—bone cancer	0.000278	0.00279	CcSEcCtD
Pioglitazone—PPARG—Regulation of retinoblastoma protein—MET—bone cancer	0.000278	0.00685	CbGpPWpGaD
Pioglitazone—PPARG—Regulation of retinoblastoma protein—CDK4—bone cancer	0.000278	0.00685	CbGpPWpGaD
Pioglitazone—Urinary tract disorder—Doxorubicin—bone cancer	0.000277	0.00278	CcSEcCtD
Pioglitazone—Oedema peripheral—Doxorubicin—bone cancer	0.000276	0.00277	CcSEcCtD
Pioglitazone—Connective tissue disorder—Doxorubicin—bone cancer	0.000276	0.00276	CcSEcCtD
Pioglitazone—Urethral disorder—Doxorubicin—bone cancer	0.000275	0.00276	CcSEcCtD
Pioglitazone—PTGS1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000275	0.00677	CbGpPWpGaD
Pioglitazone—Immune system disorder—Epirubicin—bone cancer	0.000274	0.00275	CcSEcCtD
Pioglitazone—Mediastinal disorder—Epirubicin—bone cancer	0.000273	0.00274	CcSEcCtD
Pioglitazone—Back pain—Methotrexate—bone cancer	0.000273	0.00273	CcSEcCtD
Pioglitazone—Visual impairment—Doxorubicin—bone cancer	0.00027	0.00271	CcSEcCtD
Pioglitazone—Malnutrition—Epirubicin—bone cancer	0.000264	0.00265	CcSEcCtD
Pioglitazone—Eye disorder—Doxorubicin—bone cancer	0.000262	0.00263	CcSEcCtD
Pioglitazone—Ill-defined disorder—Methotrexate—bone cancer	0.000262	0.00262	CcSEcCtD
Pioglitazone—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—bone cancer	0.000262	0.00645	CbGpPWpGaD
Pioglitazone—Anaemia—Methotrexate—bone cancer	0.000261	0.00261	CcSEcCtD
Pioglitazone—Cardiac disorder—Doxorubicin—bone cancer	0.00026	0.00261	CcSEcCtD
Pioglitazone—Flatulence—Epirubicin—bone cancer	0.00026	0.00261	CcSEcCtD
Pioglitazone—Back pain—Epirubicin—bone cancer	0.000255	0.00256	CcSEcCtD
Pioglitazone—PPARG—appendage—bone cancer	0.000255	0.135	CbGeAlD
Pioglitazone—Malaise—Methotrexate—bone cancer	0.000254	0.00255	CcSEcCtD
Pioglitazone—Muscle spasms—Epirubicin—bone cancer	0.000254	0.00254	CcSEcCtD
Pioglitazone—Immune system disorder—Doxorubicin—bone cancer	0.000253	0.00254	CcSEcCtD
Pioglitazone—Vertigo—Methotrexate—bone cancer	0.000253	0.00254	CcSEcCtD
Pioglitazone—Mediastinal disorder—Doxorubicin—bone cancer	0.000253	0.00253	CcSEcCtD
Pioglitazone—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000252	0.00622	CbGpPWpGaD
Pioglitazone—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PTGS2—bone cancer	0.000248	0.00612	CbGpPWpGaD
Pioglitazone—PPARG—Transcriptional regulation of white adipocyte differentiation—CDK4—bone cancer	0.000246	0.00606	CbGpPWpGaD
Pioglitazone—Ill-defined disorder—Epirubicin—bone cancer	0.000245	0.00245	CcSEcCtD
Pioglitazone—Malnutrition—Doxorubicin—bone cancer	0.000244	0.00245	CcSEcCtD
Pioglitazone—Anaemia—Epirubicin—bone cancer	0.000244	0.00245	CcSEcCtD
Pioglitazone—PPARG—Regulation of retinoblastoma protein—RB1—bone cancer	0.000242	0.00596	CbGpPWpGaD
Pioglitazone—Flatulence—Doxorubicin—bone cancer	0.000241	0.00241	CcSEcCtD
Pioglitazone—Myalgia—Methotrexate—bone cancer	0.00024	0.00241	CcSEcCtD
Pioglitazone—Chest pain—Methotrexate—bone cancer	0.00024	0.00241	CcSEcCtD
Pioglitazone—Arthralgia—Methotrexate—bone cancer	0.00024	0.00241	CcSEcCtD
Pioglitazone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000238	0.00239	CcSEcCtD
Pioglitazone—Malaise—Epirubicin—bone cancer	0.000238	0.00239	CcSEcCtD
Pioglitazone—Discomfort—Methotrexate—bone cancer	0.000237	0.00238	CcSEcCtD
Pioglitazone—Vertigo—Epirubicin—bone cancer	0.000237	0.00238	CcSEcCtD
Pioglitazone—Back pain—Doxorubicin—bone cancer	0.000236	0.00237	CcSEcCtD
Pioglitazone—Muscle spasms—Doxorubicin—bone cancer	0.000235	0.00235	CcSEcCtD
Pioglitazone—PPARG—Gene Expression—ZNF77—bone cancer	0.000232	0.00571	CbGpPWpGaD
Pioglitazone—Anaphylactic shock—Methotrexate—bone cancer	0.00023	0.00231	CcSEcCtD
Pioglitazone—Infection—Methotrexate—bone cancer	0.000229	0.00229	CcSEcCtD
Pioglitazone—Hypertension—Epirubicin—bone cancer	0.000228	0.00228	CcSEcCtD
Pioglitazone—Ill-defined disorder—Doxorubicin—bone cancer	0.000227	0.00227	CcSEcCtD
Pioglitazone—Nervous system disorder—Methotrexate—bone cancer	0.000226	0.00226	CcSEcCtD
Pioglitazone—Anaemia—Doxorubicin—bone cancer	0.000226	0.00226	CcSEcCtD
Pioglitazone—Arthralgia—Epirubicin—bone cancer	0.000225	0.00225	CcSEcCtD
Pioglitazone—Chest pain—Epirubicin—bone cancer	0.000225	0.00225	CcSEcCtD
Pioglitazone—Myalgia—Epirubicin—bone cancer	0.000225	0.00225	CcSEcCtD
Pioglitazone—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—bone cancer	0.000224	0.00551	CbGpPWpGaD
Pioglitazone—Skin disorder—Methotrexate—bone cancer	0.000224	0.00224	CcSEcCtD
Pioglitazone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000223	0.00224	CcSEcCtD
Pioglitazone—Hyperhidrosis—Methotrexate—bone cancer	0.000222	0.00223	CcSEcCtD
Pioglitazone—Discomfort—Epirubicin—bone cancer	0.000222	0.00223	CcSEcCtD
Pioglitazone—Malaise—Doxorubicin—bone cancer	0.00022	0.00221	CcSEcCtD
Pioglitazone—Vertigo—Doxorubicin—bone cancer	0.000219	0.0022	CcSEcCtD
Pioglitazone—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000219	0.0054	CbGpPWpGaD
Pioglitazone—CYP2C8—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000216	0.00533	CbGpPWpGaD
Pioglitazone—Anaphylactic shock—Epirubicin—bone cancer	0.000215	0.00216	CcSEcCtD
Pioglitazone—Oedema—Epirubicin—bone cancer	0.000215	0.00216	CcSEcCtD
Pioglitazone—Infection—Epirubicin—bone cancer	0.000214	0.00215	CcSEcCtD
Pioglitazone—Nervous system disorder—Epirubicin—bone cancer	0.000211	0.00212	CcSEcCtD
Pioglitazone—Hypertension—Doxorubicin—bone cancer	0.000211	0.00211	CcSEcCtD
Pioglitazone—Musculoskeletal discomfort—Methotrexate—bone cancer	0.00021	0.0021	CcSEcCtD
Pioglitazone—Skin disorder—Epirubicin—bone cancer	0.000209	0.0021	CcSEcCtD
Pioglitazone—Hyperhidrosis—Epirubicin—bone cancer	0.000208	0.00209	CcSEcCtD
Pioglitazone—Insomnia—Methotrexate—bone cancer	0.000208	0.00209	CcSEcCtD
Pioglitazone—Chest pain—Doxorubicin—bone cancer	0.000208	0.00208	CcSEcCtD
Pioglitazone—Myalgia—Doxorubicin—bone cancer	0.000208	0.00208	CcSEcCtD
Pioglitazone—Arthralgia—Doxorubicin—bone cancer	0.000208	0.00208	CcSEcCtD
Pioglitazone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000206	0.00207	CcSEcCtD
Pioglitazone—PPARG—Regulation of retinoblastoma protein—MDM2—bone cancer	0.000206	0.00508	CbGpPWpGaD
Pioglitazone—Discomfort—Doxorubicin—bone cancer	0.000205	0.00206	CcSEcCtD
Pioglitazone—Dyspnoea—Methotrexate—bone cancer	0.000205	0.00206	CcSEcCtD
Pioglitazone—PPARG—Circadian rythm related genes—GNA11—bone cancer	0.000203	0.005	CbGpPWpGaD
Pioglitazone—PPARG—Circadian rythm related genes—EZH2—bone cancer	0.000202	0.00498	CbGpPWpGaD
Pioglitazone—Anaphylactic shock—Doxorubicin—bone cancer	0.000199	0.002	CcSEcCtD
Pioglitazone—Oedema—Doxorubicin—bone cancer	0.000199	0.002	CcSEcCtD
Pioglitazone—Gastrointestinal disorder—Methotrexate—bone cancer	0.000199	0.00199	CcSEcCtD
Pioglitazone—Fatigue—Methotrexate—bone cancer	0.000198	0.00199	CcSEcCtD
Pioglitazone—Infection—Doxorubicin—bone cancer	0.000198	0.00198	CcSEcCtD
Pioglitazone—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000196	0.00197	CcSEcCtD
Pioglitazone—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000195	0.00482	CbGpPWpGaD
Pioglitazone—Nervous system disorder—Doxorubicin—bone cancer	0.000195	0.00196	CcSEcCtD
Pioglitazone—Insomnia—Epirubicin—bone cancer	0.000195	0.00195	CcSEcCtD
Pioglitazone—Skin disorder—Doxorubicin—bone cancer	0.000194	0.00194	CcSEcCtD
Pioglitazone—CYP2C19—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000193	0.00475	CbGpPWpGaD
Pioglitazone—Hyperhidrosis—Doxorubicin—bone cancer	0.000193	0.00193	CcSEcCtD
Pioglitazone—Dyspnoea—Epirubicin—bone cancer	0.000192	0.00193	CcSEcCtD
Pioglitazone—Feeling abnormal—Methotrexate—bone cancer	0.00019	0.0019	CcSEcCtD
Pioglitazone—SLCO1B3—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000187	0.00462	CbGpPWpGaD
Pioglitazone—Gastrointestinal disorder—Epirubicin—bone cancer	0.000186	0.00186	CcSEcCtD
Pioglitazone—Fatigue—Epirubicin—bone cancer	0.000186	0.00186	CcSEcCtD
Pioglitazone—Urticaria—Methotrexate—bone cancer	0.000183	0.00183	CcSEcCtD
Pioglitazone—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000182	0.00182	CcSEcCtD
Pioglitazone—Insomnia—Doxorubicin—bone cancer	0.00018	0.00181	CcSEcCtD
Pioglitazone—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00018	0.00443	CbGpPWpGaD
Pioglitazone—PPARG—Regulation of retinoblastoma protein—JUN—bone cancer	0.000179	0.00442	CbGpPWpGaD
Pioglitazone—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000178	0.00439	CbGpPWpGaD
Pioglitazone—Dyspnoea—Doxorubicin—bone cancer	0.000178	0.00178	CcSEcCtD
Pioglitazone—CYP2C8—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000178	0.00438	CbGpPWpGaD
Pioglitazone—Feeling abnormal—Epirubicin—bone cancer	0.000177	0.00178	CcSEcCtD
Pioglitazone—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000177	0.00437	CbGpPWpGaD
Pioglitazone—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000176	0.00433	CbGpPWpGaD
Pioglitazone—PTGS1—Arachidonic acid metabolism—PTGS2—bone cancer	0.000174	0.00428	CbGpPWpGaD
Pioglitazone—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000172	0.00172	CcSEcCtD
Pioglitazone—Fatigue—Doxorubicin—bone cancer	0.000172	0.00172	CcSEcCtD
Pioglitazone—Urticaria—Epirubicin—bone cancer	0.000171	0.00172	CcSEcCtD
Pioglitazone—Hypersensitivity—Methotrexate—bone cancer	0.00017	0.0017	CcSEcCtD
Pioglitazone—Asthenia—Methotrexate—bone cancer	0.000165	0.00166	CcSEcCtD
Pioglitazone—Feeling abnormal—Doxorubicin—bone cancer	0.000164	0.00165	CcSEcCtD
Pioglitazone—PPARG—Generic Transcription Pathway—NR1I2—bone cancer	0.000163	0.00402	CbGpPWpGaD
Pioglitazone—SLCO1B3—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000162	0.00398	CbGpPWpGaD
Pioglitazone—Hypersensitivity—Epirubicin—bone cancer	0.000159	0.00159	CcSEcCtD
Pioglitazone—CYP2C19—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000158	0.00391	CbGpPWpGaD
Pioglitazone—Urticaria—Doxorubicin—bone cancer	0.000158	0.00159	CcSEcCtD
Pioglitazone—Diarrhoea—Methotrexate—bone cancer	0.000157	0.00158	CcSEcCtD
Pioglitazone—Asthenia—Epirubicin—bone cancer	0.000155	0.00155	CcSEcCtD
Pioglitazone—Dizziness—Methotrexate—bone cancer	0.000152	0.00153	CcSEcCtD
Pioglitazone—Diarrhoea—Epirubicin—bone cancer	0.000147	0.00148	CcSEcCtD
Pioglitazone—Hypersensitivity—Doxorubicin—bone cancer	0.000147	0.00147	CcSEcCtD
Pioglitazone—SLCO1B3—Metabolism—NDUFA12—bone cancer	0.000146	0.00361	CbGpPWpGaD
Pioglitazone—PTGS1—Biological oxidations—CYP3A4—bone cancer	0.000146	0.0036	CbGpPWpGaD
Pioglitazone—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000146	0.00359	CbGpPWpGaD
Pioglitazone—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000144	0.00356	CbGpPWpGaD
Pioglitazone—Headache—Methotrexate—bone cancer	0.000144	0.00145	CcSEcCtD
Pioglitazone—Asthenia—Doxorubicin—bone cancer	0.000143	0.00143	CcSEcCtD
Pioglitazone—Dizziness—Epirubicin—bone cancer	0.000142	0.00143	CcSEcCtD
Pioglitazone—PPARG—Adipogenesis—RB1—bone cancer	0.000141	0.00346	CbGpPWpGaD
Pioglitazone—Diarrhoea—Doxorubicin—bone cancer	0.000136	0.00137	CcSEcCtD
Pioglitazone—Headache—Epirubicin—bone cancer	0.000135	0.00135	CcSEcCtD
Pioglitazone—Dizziness—Doxorubicin—bone cancer	0.000132	0.00132	CcSEcCtD
Pioglitazone—SLCO1B1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000126	0.0031	CbGpPWpGaD
Pioglitazone—PPARG—Metabolism—NDUFA12—bone cancer	0.000125	0.00308	CbGpPWpGaD
Pioglitazone—PTGS1—Biological oxidations—GSTP1—bone cancer	0.000125	0.00308	CbGpPWpGaD
Pioglitazone—Headache—Doxorubicin—bone cancer	0.000125	0.00125	CcSEcCtD
Pioglitazone—SLCO1B3—Metabolism—NT5C3A—bone cancer	0.000121	0.00299	CbGpPWpGaD
Pioglitazone—PPARG—Circadian rythm related genes—CDK4—bone cancer	0.000114	0.00281	CbGpPWpGaD
Pioglitazone—PPARG—Gene Expression—FUS—bone cancer	0.000113	0.00279	CbGpPWpGaD
Pioglitazone—CYP2C8—Arachidonic acid metabolism—PTGS2—bone cancer	0.000112	0.00277	CbGpPWpGaD
Pioglitazone—PTGS1—Selenium Micronutrient Network—PTGS2—bone cancer	0.000111	0.00273	CbGpPWpGaD
Pioglitazone—SLCO1B1—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000109	0.00268	CbGpPWpGaD
Pioglitazone—PPARG—Metabolism—NT5C3A—bone cancer	0.000103	0.00255	CbGpPWpGaD
Pioglitazone—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	0.0001	0.00247	CbGpPWpGaD
Pioglitazone—SLCO1B1—Metabolism—NDUFA12—bone cancer	9.84e-05	0.00242	CbGpPWpGaD
Pioglitazone—CYP2C8—Biological oxidations—CYP3A4—bone cancer	9.43e-05	0.00232	CbGpPWpGaD
Pioglitazone—CYP2C8—Metapathway biotransformation—CYP3A4—bone cancer	9.3e-05	0.00229	CbGpPWpGaD
Pioglitazone—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	9.14e-05	0.00225	CbGpPWpGaD
Pioglitazone—PTGS1—Metabolism—NDUFA12—bone cancer	8.75e-05	0.00216	CbGpPWpGaD
Pioglitazone—CYP2C19—Biological oxidations—CYP3A4—bone cancer	8.42e-05	0.00207	CbGpPWpGaD
Pioglitazone—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	8.3e-05	0.00205	CbGpPWpGaD
Pioglitazone—SLCO1B1—Metabolism—NT5C3A—bone cancer	8.15e-05	0.00201	CbGpPWpGaD
Pioglitazone—CYP2C8—Biological oxidations—GSTP1—bone cancer	8.06e-05	0.00199	CbGpPWpGaD
Pioglitazone—CYP2C8—Metapathway biotransformation—GSTP1—bone cancer	7.95e-05	0.00196	CbGpPWpGaD
Pioglitazone—PPARG—Gene Expression—NR1I2—bone cancer	7.84e-05	0.00193	CbGpPWpGaD
Pioglitazone—CYP2D6—Biological oxidations—CYP3A4—bone cancer	7.74e-05	0.00191	CbGpPWpGaD
Pioglitazone—CYP2C9—Biological oxidations—CYP3A4—bone cancer	7.67e-05	0.00189	CbGpPWpGaD
Pioglitazone—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	7.63e-05	0.00188	CbGpPWpGaD
Pioglitazone—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	7.57e-05	0.00187	CbGpPWpGaD
Pioglitazone—PPARG—Circadian rythm related genes—JUN—bone cancer	7.35e-05	0.00181	CbGpPWpGaD
Pioglitazone—PPARG—connective tissue—bone cancer	7.29e-05	0.0384	CbGeAlD
Pioglitazone—PTGS1—Metabolism—NT5C3A—bone cancer	7.25e-05	0.00179	CbGpPWpGaD
Pioglitazone—CYP2C19—Biological oxidations—GSTP1—bone cancer	7.2e-05	0.00177	CbGpPWpGaD
Pioglitazone—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	7.1e-05	0.00175	CbGpPWpGaD
Pioglitazone—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	6.68e-05	0.00165	CbGpPWpGaD
Pioglitazone—CYP2D6—Biological oxidations—GSTP1—bone cancer	6.62e-05	0.00163	CbGpPWpGaD
Pioglitazone—CYP2C9—Biological oxidations—GSTP1—bone cancer	6.56e-05	0.00162	CbGpPWpGaD
Pioglitazone—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	6.53e-05	0.00161	CbGpPWpGaD
Pioglitazone—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	6.47e-05	0.0016	CbGpPWpGaD
Pioglitazone—PPARG—Gene Expression—EIF2S1—bone cancer	5.79e-05	0.00143	CbGpPWpGaD
Pioglitazone—CYP2C8—Metabolism—NDUFA12—bone cancer	5.65e-05	0.00139	CbGpPWpGaD
Pioglitazone—PPARG—Developmental Biology—CDK4—bone cancer	5.55e-05	0.00137	CbGpPWpGaD
Pioglitazone—PPARG—Developmental Biology—MET—bone cancer	5.55e-05	0.00137	CbGpPWpGaD
Pioglitazone—SLCO1B3—Metabolism—ENO2—bone cancer	5.31e-05	0.00131	CbGpPWpGaD
Pioglitazone—CYP2C19—Metabolism—NDUFA12—bone cancer	5.04e-05	0.00124	CbGpPWpGaD
Pioglitazone—PPARG—Gene Expression—EZH2—bone cancer	5.03e-05	0.00124	CbGpPWpGaD
Pioglitazone—PPARG—tendon—bone cancer	5.01e-05	0.0264	CbGeAlD
Pioglitazone—SLCO1B3—Metabolism—DHFR—bone cancer	4.93e-05	0.00122	CbGpPWpGaD
Pioglitazone—PPARG—Circadian rythm related genes—TP53—bone cancer	4.85e-05	0.0012	CbGpPWpGaD
Pioglitazone—PPARG—bone marrow—bone cancer	4.85e-05	0.0256	CbGeAlD
Pioglitazone—CYP2C8—Metabolism—NT5C3A—bone cancer	4.68e-05	0.00115	CbGpPWpGaD
Pioglitazone—CYP2D6—Metabolism—NDUFA12—bone cancer	4.64e-05	0.00114	CbGpPWpGaD
Pioglitazone—PPARG—Developmental Biology—MMP2—bone cancer	4.63e-05	0.00114	CbGpPWpGaD
Pioglitazone—SLCO1B3—Metabolism—GNA11—bone cancer	4.61e-05	0.00114	CbGpPWpGaD
Pioglitazone—CYP2C9—Metabolism—NDUFA12—bone cancer	4.6e-05	0.00113	CbGpPWpGaD
Pioglitazone—PPARG—Metabolism—ENO2—bone cancer	4.53e-05	0.00112	CbGpPWpGaD
Pioglitazone—CYP3A4—Biological oxidations—GSTP1—bone cancer	4.33e-05	0.00107	CbGpPWpGaD
Pioglitazone—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	4.27e-05	0.00105	CbGpPWpGaD
Pioglitazone—PPARG—Metabolism—DHFR—bone cancer	4.21e-05	0.00104	CbGpPWpGaD
Pioglitazone—CYP2C19—Metabolism—NT5C3A—bone cancer	4.18e-05	0.00103	CbGpPWpGaD
Pioglitazone—SLCO1B3—Metabolism—CYP3A4—bone cancer	4.18e-05	0.00103	CbGpPWpGaD
Pioglitazone—SLCO1B3—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	4.16e-05	0.00102	CbGpPWpGaD
Pioglitazone—PPARG—Metabolism—GNA11—bone cancer	3.93e-05	0.000969	CbGpPWpGaD
Pioglitazone—PTGS1—connective tissue—bone cancer	3.89e-05	0.0205	CbGeAlD
Pioglitazone—CYP2D6—Metabolism—NT5C3A—bone cancer	3.84e-05	0.000948	CbGpPWpGaD
Pioglitazone—CYP2C9—Metabolism—NT5C3A—bone cancer	3.81e-05	0.00094	CbGpPWpGaD
Pioglitazone—SLCO1B3—Metabolism—GSTP1—bone cancer	3.57e-05	0.00088	CbGpPWpGaD
Pioglitazone—SLCO1B1—Metabolism—ENO2—bone cancer	3.57e-05	0.00088	CbGpPWpGaD
Pioglitazone—PPARG—Metabolism—CYP3A4—bone cancer	3.56e-05	0.000878	CbGpPWpGaD
Pioglitazone—PPARG—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	3.55e-05	0.000874	CbGpPWpGaD
Pioglitazone—PPARG—Developmental Biology—MMP9—bone cancer	3.48e-05	0.000858	CbGpPWpGaD
Pioglitazone—SLCO1B1—Metabolism—DHFR—bone cancer	3.31e-05	0.000816	CbGpPWpGaD
Pioglitazone—PTGS1—Metabolism—ENO2—bone cancer	3.18e-05	0.000783	CbGpPWpGaD
Pioglitazone—SLCO1B1—Metabolism—GNA11—bone cancer	3.1e-05	0.000763	CbGpPWpGaD
Pioglitazone—PPARG—Metabolism—GSTP1—bone cancer	3.05e-05	0.000751	CbGpPWpGaD
Pioglitazone—CYP3A4—Metabolism—NDUFA12—bone cancer	3.03e-05	0.000748	CbGpPWpGaD
Pioglitazone—PTGS1—Metabolism—DHFR—bone cancer	2.95e-05	0.000726	CbGpPWpGaD
Pioglitazone—PPARG—Developmental Biology—EGFR—bone cancer	2.81e-05	0.000694	CbGpPWpGaD
Pioglitazone—SLCO1B1—Metabolism—CYP3A4—bone cancer	2.81e-05	0.000692	CbGpPWpGaD
Pioglitazone—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.79e-05	0.000688	CbGpPWpGaD
Pioglitazone—PTGS1—Metabolism—GNA11—bone cancer	2.75e-05	0.000679	CbGpPWpGaD
Pioglitazone—PTGS1—tendon—bone cancer	2.68e-05	0.0141	CbGeAlD
Pioglitazone—PTGS1—spinal cord—bone cancer	2.58e-05	0.0136	CbGeAlD
Pioglitazone—CYP3A4—Metabolism—NT5C3A—bone cancer	2.51e-05	0.00062	CbGpPWpGaD
Pioglitazone—PTGS1—Metabolism—CYP3A4—bone cancer	2.5e-05	0.000615	CbGpPWpGaD
Pioglitazone—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.48e-05	0.000612	CbGpPWpGaD
Pioglitazone—SLCO1B1—Metabolism—GSTP1—bone cancer	2.4e-05	0.000592	CbGpPWpGaD
Pioglitazone—PTGS1—Metabolism—GSTP1—bone cancer	2.13e-05	0.000526	CbGpPWpGaD
Pioglitazone—CYP2C8—Metabolism—ENO2—bone cancer	2.05e-05	0.000506	CbGpPWpGaD
Pioglitazone—CYP2C8—Metabolism—DHFR—bone cancer	1.9e-05	0.000469	CbGpPWpGaD
Pioglitazone—SLCO1B3—Metabolism—PTGS2—bone cancer	1.85e-05	0.000456	CbGpPWpGaD
Pioglitazone—CYP2C19—Metabolism—ENO2—bone cancer	1.83e-05	0.000451	CbGpPWpGaD
Pioglitazone—CYP2C8—Metabolism—GNA11—bone cancer	1.78e-05	0.000438	CbGpPWpGaD
Pioglitazone—CYP2C19—Metabolism—DHFR—bone cancer	1.7e-05	0.000419	CbGpPWpGaD
Pioglitazone—CYP2D6—Metabolism—ENO2—bone cancer	1.68e-05	0.000415	CbGpPWpGaD
Pioglitazone—CYP2C9—Metabolism—ENO2—bone cancer	1.67e-05	0.000412	CbGpPWpGaD
Pioglitazone—CYP2C8—Metabolism—CYP3A4—bone cancer	1.61e-05	0.000397	CbGpPWpGaD
Pioglitazone—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.6e-05	0.000395	CbGpPWpGaD
Pioglitazone—CYP2C19—Metabolism—GNA11—bone cancer	1.59e-05	0.000391	CbGpPWpGaD
Pioglitazone—PPARG—Metabolism—PTGS2—bone cancer	1.58e-05	0.000389	CbGpPWpGaD
Pioglitazone—CYP2D6—Metabolism—DHFR—bone cancer	1.56e-05	0.000385	CbGpPWpGaD
Pioglitazone—CYP2C9—Metabolism—DHFR—bone cancer	1.55e-05	0.000382	CbGpPWpGaD
Pioglitazone—CYP2D6—Metabolism—GNA11—bone cancer	1.46e-05	0.00036	CbGpPWpGaD
Pioglitazone—CYP2C9—Metabolism—GNA11—bone cancer	1.45e-05	0.000357	CbGpPWpGaD
Pioglitazone—CYP2C19—Metabolism—CYP3A4—bone cancer	1.44e-05	0.000355	CbGpPWpGaD
Pioglitazone—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.43e-05	0.000353	CbGpPWpGaD
Pioglitazone—CYP2C8—Metabolism—GSTP1—bone cancer	1.38e-05	0.00034	CbGpPWpGaD
Pioglitazone—CYP2D6—Metabolism—CYP3A4—bone cancer	1.32e-05	0.000326	CbGpPWpGaD
Pioglitazone—CYP2C9—Metabolism—CYP3A4—bone cancer	1.31e-05	0.000323	CbGpPWpGaD
Pioglitazone—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.31e-05	0.000322	CbGpPWpGaD
Pioglitazone—SLCO1B1—Metabolism—PTGS2—bone cancer	1.24e-05	0.000306	CbGpPWpGaD
Pioglitazone—CYP2C19—Metabolism—GSTP1—bone cancer	1.23e-05	0.000303	CbGpPWpGaD
Pioglitazone—CYP2D6—Metabolism—GSTP1—bone cancer	1.13e-05	0.000279	CbGpPWpGaD
Pioglitazone—CYP2C9—Metabolism—GSTP1—bone cancer	1.12e-05	0.000277	CbGpPWpGaD
Pioglitazone—PTGS1—Metabolism—PTGS2—bone cancer	1.11e-05	0.000273	CbGpPWpGaD
Pioglitazone—CYP3A4—Metabolism—ENO2—bone cancer	1.1e-05	0.000271	CbGpPWpGaD
Pioglitazone—CYP3A4—Metabolism—DHFR—bone cancer	1.02e-05	0.000252	CbGpPWpGaD
Pioglitazone—CYP3A4—Metabolism—GNA11—bone cancer	9.55e-06	0.000235	CbGpPWpGaD
Pioglitazone—CYP3A4—Metabolism—GSTP1—bone cancer	7.4e-06	0.000182	CbGpPWpGaD
Pioglitazone—CYP2C8—Metabolism—PTGS2—bone cancer	7.14e-06	0.000176	CbGpPWpGaD
Pioglitazone—CYP2C19—Metabolism—PTGS2—bone cancer	6.38e-06	0.000157	CbGpPWpGaD
Pioglitazone—CYP2D6—Metabolism—PTGS2—bone cancer	5.87e-06	0.000145	CbGpPWpGaD
Pioglitazone—CYP2C9—Metabolism—PTGS2—bone cancer	5.81e-06	0.000143	CbGpPWpGaD
Pioglitazone—CYP3A4—Metabolism—PTGS2—bone cancer	3.83e-06	9.45e-05	CbGpPWpGaD
